Tadashi Fujisawa, CEO Mebiopharm Co., Ltd.

(TOKYO PRO Market Stock Codes: 4580)

March 27, 2013

## Announcement of Applying for Delisting from TOKYO PRO Market

Mebiopharm Co., Ltd. (Tokyo, Japan, CEO: Tadashi Fujisawa, hereinafter 'MEBIO') announces that MEBIO apply for voluntary delisting of its shares from TOKYO PRO Market with the extraordinary resolution of Shareholders Meeting.

## 1. Purpose and reason for delisting

MEBIO has listed for 1st listing on TOKYO AIM (current TOKYO PRO Market) in July 2011 and has been able to expand a scope of business, customer and field of work with fully benefiting the merits for its flexible features.

This led us to proceed a new clinical study for MBP-426, main pipeline product for anti-cancer drug, to enhance basic research such as nano formulation of nucleic acid medicine and development of diagnostic agent, and to drive a business deployment of generic product using nano particle.

Mebio will promote business alliance for developing these further continuously. In order to do so, MEBIO believes that it is desirable to delist from TOKYO PRO Market by using their specific system and expand a business freely. Mebio also believes that this will contribute a progress of MEBIO management and MEBIO business for the future, and then this will maximize the value of shareholders.

Therefore, MEBIO intends to apply for delisting according to the rule of TOKYO PRO Market.

## 2. Extraordinary shareholders' meeting and schedule

This will be discussed at the extraordinary shareholders' meeting since extraordinary resolution at the shareholders' meeting is necessary to apply for delisting.

(1) Extraordinary shareholders' meeting: May 10, 2013
(2) Apply for delisting: May 10, 2013
(3) Delisting: June 7, 2013

MEBIO will be delisted 20 business days after its filing of the application.